ALTIMMUNE, INC. Business Combination, Acquisition Related Costs
ALTIMMUNE, INC. (ALT) reported Business Combination, Acquisition Related Costs of $1.51 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-04-02.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessCombinationAcquisitionRelatedCosts · last filed 2018-04-02
- ALTIMMUNE, INC. business combination, acquisition related costs for fiscal 2017 was $1.51M, a 125.32% increase from fiscal 2016.
- ALTIMMUNE, INC. business combination, acquisition related costs for fiscal 2016 was $671.25K.
| Period end | Business Combination, Acquisition Related Costs 12 month |
|---|---|
| 2017-12-31 | $1.51M 10-K · filed 2018-04-02 |
| 2016-12-31 | $671.25K 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |